AZ, Junshi Part Ways Amid China IO Commercial Struggle

 
• By Dexter Jie Yan

Multinationals including AstraZeneca are retreating from China’s overcrowded immuno-oncology market but one exception - Pfizer - remains steadfast.

AZ the latest multinational pharma to opt out.
Multinationals start to opt out of tie-ups with Chinese immuno-oncology biotechs in packed domestic market • Source: Alamy

More from China

More from Focus On Asia